

## Zaltrap® (ziv-aflibercept) (Intravenous)

Document Number: IC-0161

Last Review Date: 03/01/2022

Date of Origin: 02/07/2013

Dates Reviewed: 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 2/2018, 5/2018, 09/2018, 12/2018, 03/2019, 06/2019, 9/2019, 12/2019, 03/2020, 06/2020, 09/2020, 03/2022

### I. Length of Authorization

Coverage will be provided for six months and may be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC Unit]:

- Zaltrap 100 mg/4 mL injection: 2 vials per 28 days
- Zaltrap 200 mg/8 mL injection: 4 vials per 28 days

#### B. Max Units (per dose and over time) [HCPCS Unit]:

- 500 billable units every 14 days

### III. Initial Approval Criteria <sup>1,2,6</sup>

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

#### Universal Criteria <sup>1</sup>

- Patient does not have recent history of severe hemorrhage; **AND**
- Ziv-aflibercept will be not administered for at least 4 weeks following major surgery; **AND**
- Patient does not have a surgical wound that has not fully healed; **AND**

#### Colorectal Cancer (CRC) † <sup>1,2,6</sup>

- Patient has metastatic disease that is resistant to or has progressed following an oxaliplatin-containing regimen (e.g., FOLFOX, CapeOX) †; **AND**
  - Used in combination with FOLFIRI (fluorouracil, leucovorin, and irinotecan); **OR**
- Used as primary treatment for patients with unresectable metastases and previous adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CapeOX (capecitabine and oxaliplatin) within the past 12 months; **AND**

- Used in combination with irinotecan or FOLFIRI; **OR**
- Used as subsequent therapy for progression of advanced or metastatic disease in patients not previously treated with irinotecan-based therapy; **AND**
  - Used in combination with irinotecan or FOLFIRI

† FDA-labeled indication(s); ‡ Compendia Recommended Indication(s); Ⓞ Orphan Drug

#### IV. Renewal Criteria <sup>1,2</sup>

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment a defined by stabilization of disease or decrease in size or spread of tumor; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: hemorrhage, gastrointestinal perforation, fistula formation, uncontrolled hypertension, hypertensive crisis, hypertensive encephalopathy, wound healing complications, arterial thromboembolic events, proteinuria ( $\geq 2$  g/24 hours), nephrotic syndrome, thrombotic microangiopathy (TMA), neutropenic complications, reversible posterior leukoencephalopathy syndrome (RPLS), severe diarrhea/dehydration, etc.

#### V. Dosage/Administration <sup>1,2</sup>

Indication	Dose
Colorectal Cancer	Administer 4 mg/kg of actual body weight as an intravenous (IV) infusion every two weeks, until disease progression or unacceptable toxicity.

#### VI. Billing Code/Availability Information

HCPCS Code:

- J9400 – Injection, ziv-aflibercept, 1 mg; 1 billable unit = 1 mg

NDC(s):

- Zaltrap 100 mg/4 mL solution, single-dose vial: 00024-5840-xx
- Zaltrap 200 mg/8 mL solution, single-dose vial: 00024-5841-xx

#### VII. References

1. Zaltrap [package insert]. Bridgewater, NJ; Sanofi-Aventis U.S. LLC; December 2020. Accessed January 2022.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) ziv-aflibercept. National Comprehensive Cancer Network, 2022. The NCCN

Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2022.

3. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. *J Oncol Pract.* 2018 Mar;14(3):e130-e136.
4. Hematology/Oncology Pharmacy Association (2019). *Intravenous Cancer Drug Waste Issue Brief.* Retrieved from [http://www.hoparx.org/images/hopa/advocacy/IssueBriefs/Drug\\_Waste\\_2019.pdf](http://www.hoparx.org/images/hopa/advocacy/IssueBriefs/Drug_Waste_2019.pdf)
5. Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. *BMJ.* 2016 Feb 29;352:i788.
6. Tabernero J, Paccard C, Chiron M, et al. Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial. *Journal of Clinical Oncology*35, no. 4\_suppl(February 01, 2017)592-592. DOI: 10.1200/JCO.2017.35.4\_suppl.592
7. Sanofi. A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen. Available from: <https://clinicaltrials.gov/ct2/show/NCT00561470?term=NCT00561470&draw=2&rank=1>. ClinicalTrials.gov Identifier: NCT00561470. Accessed January 2020.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of large intestines
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C78.00	Secondary malignant neoplasm of unspecified lung

### ZALTRAP® (ziv-aflibercept) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2022, Magellan Rx Management

ICD-10	ICD-10 Description
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
Z85.038	Personal history of other malignant neoplasm of large intestine
Z85.068	Personal history of other malignant neoplasm of small intestine

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at:

<https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC